SK280991B6 - 19,11-premostené 4-estrény, spôsob ich výroby, farmaceutický prostriedok tieto látky obsahujúci, ich použitie a medziprodukty na ich výrobu - Google Patents

19,11-premostené 4-estrény, spôsob ich výroby, farmaceutický prostriedok tieto látky obsahujúci, ich použitie a medziprodukty na ich výrobu Download PDF

Info

Publication number
SK280991B6
SK280991B6 SK494-95A SK49495A SK280991B6 SK 280991 B6 SK280991 B6 SK 280991B6 SK 49495 A SK49495 A SK 49495A SK 280991 B6 SK280991 B6 SK 280991B6
Authority
SK
Slovakia
Prior art keywords
benzo
dihydro
hydroxy
group
estra
Prior art date
Application number
SK494-95A
Other languages
English (en)
Slovak (sk)
Other versions
SK49495A3 (en
Inventor
Eckhard Ottow
Wolfgang Schwede
Wolfgang Halfbrodt
Karl-Heinrich Fritzemeister
Rolf Krattenmacher
Original Assignee
Schering Aktiengesellschaft
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Schering Aktiengesellschaft filed Critical Schering Aktiengesellschaft
Publication of SK49495A3 publication Critical patent/SK49495A3/sk
Publication of SK280991B6 publication Critical patent/SK280991B6/sk

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J53/00—Steroids in which the cyclopenta(a)hydrophenanthrene skeleton has been modified by condensation with a carbocyclic rings or by formation of an additional ring by means of a direct link between two ring carbon atoms, including carboxyclic rings fused to the cyclopenta(a)hydrophenanthrene skeleton are included in this class
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J53/00—Steroids in which the cyclopenta(a)hydrophenanthrene skeleton has been modified by condensation with a carbocyclic rings or by formation of an additional ring by means of a direct link between two ring carbon atoms, including carboxyclic rings fused to the cyclopenta(a)hydrophenanthrene skeleton are included in this class
    • C07J53/002—Carbocyclic rings fused
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/18—Feminine contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/34—Gestagens
SK494-95A 1992-10-13 1993-10-13 19,11-premostené 4-estrény, spôsob ich výroby, farmaceutický prostriedok tieto látky obsahujúci, ich použitie a medziprodukty na ich výrobu SK280991B6 (sk)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE4235220A DE4235220A1 (de) 1992-10-13 1992-10-13 Gestagen wirksame 19,11ß-überbrückte 4-Estrene
PCT/EP1993/002823 WO1994009025A1 (de) 1992-10-13 1993-10-13 Gestagen wirksame 19,11-überbrückte 4-estrene

Publications (2)

Publication Number Publication Date
SK49495A3 SK49495A3 (en) 1995-08-09
SK280991B6 true SK280991B6 (sk) 2000-10-09

Family

ID=6470806

Family Applications (1)

Application Number Title Priority Date Filing Date
SK494-95A SK280991B6 (sk) 1992-10-13 1993-10-13 19,11-premostené 4-estrény, spôsob ich výroby, farmaceutický prostriedok tieto látky obsahujúci, ich použitie a medziprodukty na ich výrobu

Country Status (25)

Country Link
US (2) US5523298A (no)
EP (1) EP0664811B1 (no)
JP (1) JP3302366B2 (no)
KR (1) KR100341066B1 (no)
CN (1) CN1052238C (no)
AT (1) ATE156837T1 (no)
AU (1) AU677019B2 (no)
BR (1) BR9307232A (no)
CA (1) CA2146962A1 (no)
CZ (1) CZ284187B6 (no)
DE (2) DE4235220A1 (no)
DK (1) DK0664811T3 (no)
ES (1) ES2108298T3 (no)
FI (1) FI951760A (no)
GR (1) GR3024940T3 (no)
HU (1) HU223315B1 (no)
IL (1) IL107232A (no)
NO (1) NO305440B1 (no)
NZ (1) NZ256865A (no)
PL (1) PL179764B1 (no)
RU (1) RU2157814C2 (no)
SK (1) SK280991B6 (no)
TW (1) TW341575B (no)
WO (1) WO1994009025A1 (no)
ZA (1) ZA937614B (no)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE4235220A1 (de) * 1992-10-13 1994-06-16 Schering Ag Gestagen wirksame 19,11ß-überbrückte 4-Estrene
DE4413184A1 (de) * 1994-04-12 1995-10-19 Schering Ag 10,11-C¶3¶-überbrückte Steroide
DE4413185A1 (de) * 1994-04-12 1995-10-19 Schering Ag 11beta,19-überbrückte 13alpha-Alkylsteroide
US5912006A (en) * 1996-08-28 1999-06-15 Eboc, Inc. Compositions and methods for alleviating discomforting menstrual pain
AU2002219218A1 (en) * 2000-12-28 2002-07-16 Schering Ag Method for screening for progesterone receptor isoform-specific ligands
US20040121304A1 (en) * 2001-12-21 2004-06-24 Ulrike Fuhrmann Method for screening for progesterone receptor isoform-specific ligands and for tissue-selective progesterone receptor ligands
GB0219345D0 (en) * 2002-08-20 2002-09-25 Givaudan Sa Improvements in or relating to organic compounds

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3465010A (en) * 1966-11-22 1969-09-02 Searle & Co 17 - (unsaturated hydrocarbon - substituted) 11,13beta - dialkylgon -4 - ene - 3,17beta-diols and esters thereof
US5446178A (en) * 1987-03-18 1995-08-29 Schering Aktiengesellschaft Process for preparing 19,11β-bridged steroids
DE3708942A1 (de) * 1987-03-18 1988-09-29 Schering Ag 19,11ss-ueberbrueckte steroide, deren herstellung und diese enthaltende pharmazeutische praeparate
DE3717169A1 (de) * 1987-05-19 1988-12-01 Schering Ag 19,11ss-ueberbrueckte steroide, deren herstellung und diese enthaltende pharmazeutische praeparate
DE3832303A1 (de) * 1988-09-20 1990-04-12 Schering Ag 11ss-phenyl-14ssh-steroide
DE3917274A1 (de) * 1989-05-24 1990-11-29 Schering Ag 9(alpha)-hydroxy-19, 11(beta)-ueberbrueckte steroide, deren herstellung und diese enthaltende pharmazeutische praeparate
DE4038128A1 (de) * 1990-11-27 1992-06-04 Schering Ag 8-en-19, 11(beta)-ueberbrueckte steroide, deren herstellung und diese enthaltende pharmazeutische praeparate
DE4235220A1 (de) * 1992-10-13 1994-06-16 Schering Ag Gestagen wirksame 19,11ß-überbrückte 4-Estrene

Also Published As

Publication number Publication date
ZA937614B (en) 1994-05-23
CZ284187B6 (cs) 1998-09-16
ES2108298T3 (es) 1997-12-16
PL179764B1 (pl) 2000-10-31
US5523298A (en) 1996-06-04
EP0664811A1 (de) 1995-08-02
HU223315B1 (hu) 2004-05-28
JP3302366B2 (ja) 2002-07-15
PL308349A1 (en) 1995-07-24
RU2157814C2 (ru) 2000-10-20
AU677019B2 (en) 1997-04-10
RU95109891A (ru) 1997-02-10
WO1994009025A1 (de) 1994-04-28
EP0664811B1 (de) 1997-08-13
IL107232A (en) 1998-06-15
CA2146962A1 (en) 1994-04-28
HUT71523A (en) 1995-12-28
NO951444D0 (no) 1995-04-12
NO305440B1 (no) 1999-05-31
TW341575B (en) 1998-10-01
BR9307232A (pt) 1999-08-24
SK49495A3 (en) 1995-08-09
US5703066A (en) 1997-12-30
NO951444L (no) 1995-06-13
IL107232A0 (en) 1994-01-25
NZ256865A (en) 1996-04-26
AU5177493A (en) 1994-05-09
HU9501057D0 (en) 1995-06-28
KR100341066B1 (ko) 2002-12-06
CZ91995A3 (en) 1995-09-13
JPH08502276A (ja) 1996-03-12
KR950703576A (ko) 1995-09-20
FI951760A0 (fi) 1995-04-12
ATE156837T1 (de) 1997-08-15
DE59307133D1 (de) 1997-09-18
FI951760A (fi) 1995-04-12
CN1092428A (zh) 1994-09-21
GR3024940T3 (en) 1998-01-30
CN1052238C (zh) 2000-05-10
DK0664811T3 (da) 1998-03-30
DE4235220A1 (de) 1994-06-16

Similar Documents

Publication Publication Date Title
KR20100017780A (ko) 17베타-시아노-18ａ-호모-19-노르-안드로스트-4-엔 유도체, 그의 용도, 및 상기 유도체를 함유하는 의약
KR101440640B1 (ko) 18-메틸-19-노르안드로스트-4-엔-17,17-스피로에테르 (18-메틸-19-노르-20-스피록스-4-엔-3-온), 및 이를 함유하는 제약 제제
SK18899A3 (en) 7'alpha'-('xi'-aminoalkyl)estratrienes, process for preparing the same, pharmaceutical preparations containing said 7'alpha'-('xi'- -aminoalkyl)estratrienes and their use for preparing medicaments
KR20070093443A (ko) 18-메틸-19-노르-17-프레근-4-엔-21,17-카르보락톤 및 이를포함하는 제약 제제
US6706700B2 (en) 14β,15β-methylene-17α-hydroxymethyl-androgens
KR20100028554A (ko) 17β-시아노-19-노르-안드로스트-4-엔 유도체, 그의 용도, 및 상기 유도체를 함유하는 의약
SK280991B6 (sk) 19,11-premostené 4-estrény, spôsob ich výroby, farmaceutický prostriedok tieto látky obsahujúci, ich použitie a medziprodukty na ich výrobu
KR20100037596A (ko) 17β-시아노-19-안드로스트-4-엔 유도체, 그의 용도, 및 상기 유도체를 함유하는 의약
SK78897A3 (en) 14'alpha',17'alpha'-c2-bridged 19-nor-progesterone derivatives, pharmaceutical composition containing the same and intermediate products for producing the same
JP5600069B2 (ja) １７−（１’−プロペニル）−１７−３’−オキシドエストラ−４−エン−３−オン誘導体、その使用及び当該誘導体を含む医薬品
KR100730010B1 (ko) 신규 안드로겐
WO1995011915A1 (de) 10,11β-C2-ÜBERBRÜCKTE STEROIDE
WO1995027726A1 (de) 10,11-c3-überbrückte steroide
WO1995027725A1 (de) 11β,19-ÜBERBRÜCKTE 13α-ALKYLSTEROIDE
DE19535851A1 (de) 18-Norsteroide mit gestagener Wirkung